Tarrik Zaid1, Jennifer Burzawa1, Karen Basen-Engquist2, Diane C Bodurka1, Lois M Ramondetta1, Jubilee Brown1, Michael Frumovitz3. 1. Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 2. Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3. Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: mfrumovitz@mdanderson.org.
Abstract
OBJECTIVE: To determine the feasibility of using social media to perform cross-sectional epidemiologic and quality-of-life research on patients with rare gynecologic tumors, we performed a survey of patients with neuroendocrine tumors of the cervix using Facebook. METHODS: After approval from our Institutional Review Board, a support group of patients with neuroendocrine tumors of the cervix was identified on Facebook. Group members were asked to complete a survey comprising 84 questions evaluating clinical presentation; treatment; recurrence; quality of life; and sexual function. RESULTS: The survey was posted for 30 days, during which 57 women responded from 8 countries across 4 continents treated at 51 centers. All respondents provided a detailed clinical and tumor history. The mean age was 38.5 years. The stage distribution was stage I, 36 patients (63%); II, 13 (23%); III, 2 (4%); and IV, 6 (11%). Forty-nine patients (86%) had small cell and 8 (14%) had large cell tumors. Forty-five of the respondents (79%) had completed primary therapy and were without evidence of disease. Five (9%) had recurrence, 3 (5%) had persistent disease after therapy, and 4 (7%) were still under treatment. Forty-one patients (72%) reported symptoms at time of presentation. Thirty-seven patients (65%) received multimodality primary therapy. Quality of life instruments demonstrated high scores for anxiety and a negative impact of anxiety and cancer on functional and emotional well-being. Sexual function scores did not differ significantly between respondents and the PROMIS reference population. CONCLUSIONS: Use of a social media network to perform epidemiologic and quality of life research on patients with rare gynecologic tumors is feasible and permits such research to be conducted efficiently and rapidly.
OBJECTIVE: To determine the feasibility of using social media to perform cross-sectional epidemiologic and quality-of-life research on patients with rare gynecologic tumors, we performed a survey of patients with neuroendocrine tumors of the cervix using Facebook. METHODS: After approval from our Institutional Review Board, a support group of patients with neuroendocrine tumors of the cervix was identified on Facebook. Group members were asked to complete a survey comprising 84 questions evaluating clinical presentation; treatment; recurrence; quality of life; and sexual function. RESULTS: The survey was posted for 30 days, during which 57 women responded from 8 countries across 4 continents treated at 51 centers. All respondents provided a detailed clinical and tumor history. The mean age was 38.5 years. The stage distribution was stage I, 36 patients (63%); II, 13 (23%); III, 2 (4%); and IV, 6 (11%). Forty-nine patients (86%) had small cell and 8 (14%) had large cell tumors. Forty-five of the respondents (79%) had completed primary therapy and were without evidence of disease. Five (9%) had recurrence, 3 (5%) had persistent disease after therapy, and 4 (7%) were still under treatment. Forty-one patients (72%) reported symptoms at time of presentation. Thirty-seven patients (65%) received multimodality primary therapy. Quality of life instruments demonstrated high scores for anxiety and a negative impact of anxiety and cancer on functional and emotional well-being. Sexual function scores did not differ significantly between respondents and the PROMIS reference population. CONCLUSIONS: Use of a social media network to perform epidemiologic and quality of life research on patients with rare gynecologic tumors is feasible and permits such research to be conducted efficiently and rapidly.
Authors: J Albores-Saavedra; D Gersell; C B Gilks; D E Henson; G Lindberg; H Santiago; R E Scully; E Silva; L H Sobin; F J Tavassoli; W D Travis; J M Woodruff Journal: Arch Pathol Lab Med Date: 1997-01 Impact factor: 5.534
Authors: Akila N Viswanathan; Michael T Deavers; Anuja Jhingran; Pedro T Ramirez; Charles Levenback; Patricia J Eifel Journal: Gynecol Oncol Date: 2004-04 Impact factor: 5.482
Authors: Diana D Jeffery; Lisa Barbera; Barbara L Andersen; Amy K Siston; Anuja Jhingran; Shirley R Baron; Jennifer Barsky Reese; Deborah J Coady; Jeanne Carter; Kathryn E Flynn Journal: J Psychosoc Oncol Date: 2015
Authors: Casey J Allen; Danny Yakoub; Francisco Igor Macedo; Austin R Dosch; Jessica Brosch; Vikas Dudeja; Ronda Ayala; Nipun B Merchant Journal: Ann Surg Date: 2018-10 Impact factor: 12.969
Authors: Shawna L Stratton; Horace J Spencer; William W Greenfield; Gordon Low; Wilbur C Hitt; Charles M Quick; Susanne K Jeffus; Victoria Blackmon; Mayumi Nakagawa Journal: Clin Trials Date: 2015-01-09 Impact factor: 2.486
Authors: M Frumovitz; M F Munsell; J K Burzawa; L A Byers; P Ramalingam; J Brown; R L Coleman Journal: Gynecol Oncol Date: 2016-11-04 Impact factor: 5.482
Authors: Alexis Koskan; Lynne Klasko; Stacy N Davis; Clement K Gwede; Kristen J Wells; Ambuj Kumar; Natalia Lopez; Cathy D Meade Journal: Am J Public Health Date: 2014-05-15 Impact factor: 9.308
Authors: Michael Frumovitz; Jennifer K Burzawa; Lauren A Byers; Yasmin A Lyons; Preetha Ramalingam; Robert L Coleman; Jubilee Brown Journal: Gynecol Oncol Date: 2016-04-15 Impact factor: 5.482